Zostavax
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background On October 20, 2017, the U.S. Food and Drug Administration approved Shingrix, a new recombinant zoster vaccine (RZV…
BACKGROUND
Patients on immunosuppressive therapy are at a greater risk for herpes zoster reactivation and are more likely to have…
Zostavax, a live attenuated vaccine against shingles (herpes zoster) has been available in Switzerland since 2008. In a…
Oka varicella vaccine was developed to confer active immunity to varicella-zoster virus (VZV) in immunocompromized and…
In Germany, a vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia (PHN) in adults aged 50 years and older has…
Varicella-zoster virus is the causal agent of varicella and herpes zoster (HZ) in humans. HZ results from reactivation of latent…
Herpes zoster (HZ) results from reactivation of the varicella-zoster virus (VZV), which remains latent in the dorsal root ganglia…
Background:
Herpes zoster (HZ), or shingles, is caused by the reactivation of latent varicella-zoster virus (VZV) years after an…